Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized clinical trials.

ABSTRACT:

Aim

To investigate the association between treatment with dulaglutide and glycaemic variability (GV) in adult patients with type 2 diabetes mellitus (T2D).

Materials and methods

Post hoc analyses of six randomized, phase 3 studies were conducted to investigate the association between treatment with dulaglutide 1.5 mg once weekly and GV in adult patients with T2D. Using data from seven- and eight-point self-monitored plasma glucose (SMPG) profiles over up to 28 weeks of treatment, GV in within- and between-day SMPG, and between-day fasting glucose from SMPG (FSMPG) was assessed according to standard deviation and coefficient of variation.

Results

Pooled data from five studies with dulaglutide as monotherapy or added to oral glucose-lowering medication, without concomit

SUBMITTER: Jodar E 

PROVIDER: S-EPMC9300025 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature